UK – NICE nod for Takeda’s Adcetris in advanced stage CTCL

Takeda has announced the National Institute for Health and Care Excellence (NICE) recommendation of its advanced cutaneous T-cell lymphoma (CTCL) drug Adcetris (brentuximab vedotin).

The indication is for treating adult patients with CD-30 positive advanced versions of the disease, after at least one prior systemic therapy. The approval is due to close collaborative working between Takeda, the clinical and patient community, as well as NICE and NHS England.

The treatment already has European approval based on an open-label Phase III ALCANZA trial. The results showed that a single dose provided a statistically significant improvement compared to current treatment methods such as the control arm of methotrexate or bexarotene. Median progression-free survival was 16.7 months compared to 3.5 months with methotrexate or bexarotene…